Objective: To study the association between the progression of HIV disease and HIV neutralization and enhancement measured in the presence of human complement.
Design: Two studies were performed: (1) longitudinal measurement of the complement-dependent enhancing antibodies in parallel with T-cell subset determination in 55 serum samples from seven HIV-infected patients, and (2) determination of the titres of neutralizing and enhancing antibodies in stored samples of 21 HIV-asymptomatic patients obtained between 1986 and 1987 and follow-up of the patients until October 1992.
Methods: HIV-1 [human T-lymphotropic virus (HTLV)IIIB strain, 100 median tissue culture infective dose (TCID50)] was incubated with twofold dilutions of sera in the presence of human complement (final dilution, 1:4) and added to MT-4 cells. HIV growth was monitored daily for 5 days using the reclustering inhibition and p24 immunofluorescence assays.
Results: A significant negative correlation between the titres of enhancing antibodies and CD4+ cell count was found in longitudinal measurements. In the prospective studies, marked differences were observed between patients with undetectable, low, or high titres of enhancing antibodies in the clinical course of HIV disease: CD4+ cell counts and percentages decreased more rapidly in the high titre group within 3 years. After 5 years, AIDS developed in five out of six patients in the high titre group but only in five out of 15 of the low titre group (P < 0.05). A similar difference was observed between patients with and without neutralizing antibodies.
Conclusions: Measurement of HIV neutralization and enhancement in complement-containing serum samples using a complement receptor carrying target may provide data of clinical relevance. Neutralization appears to be associated with a favourable prognosis whereas high titre enhancing antibodies predict rapid progression of HIV disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00002030-199405000-00005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma.
Indian J Nephrol
July 2024
Department of Nephrology, Asian Institute of Nephrology and Urology, Dilsukhnagar Hyderabad, India.
Multiple myeloma (MM) represents a difficult-to-treat plasma cell malignancy and the second most common hematologic malignancy in adults, significantly impacting kidney function. The spectrum of kidney involvement in MM is broad, encompassing electrolyte imbalances, tubular injury, and even rare glomerular diseases. The evolution of MM treatment modalities has led to notable improvements in the long-term survival of patients experiencing kidney-related complications.
View Article and Find Full Text PDFRecombinant nanobody expressed by transgenic chimeric chickens eliminated vertical transmission of avian leukosis virus subgroup J.
Vet Microbiol
January 2025
College of Animal Science and Technology, Guangxi University, China. Electronic address:
Because of the vertical transmission of avian leukosis virus subgroup J (ALV-J), control of ALV-J in breed of chicken is still a serious issue. Blocking vertical transmission using antibodies is a potential strategy, but its high cost limits its application. We artificially designed recombinant nanobody (Nb) and efficiently expressed and secreted them in three primary chicken cells cultured in vitro by adenovirus delivery.
View Article and Find Full Text PDFEnhancing farmer awareness: Vertical transmission of Neospora caninum in aborting cattle and the value of diagnostics tools.
Vet Parasitol
January 2025
Institute of Parasitology, Vetsuisse Faculty, University of Bern, Länggassstrasse 122, Bern 3012, Switzerland. Electronic address:
The protozoan parasite Neospora caninum is an important cause of abortion in cattle. Infection occurs horizontally by ingestion of oocysts shed by canids or vertically, from an infected dam to the foetus, and may result in abortion, stillbirth, or the birth of subclinically infected offspring. We estimated the occurrence of N.
View Article and Find Full Text PDFProtection of β2GPI-Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation.
Blood
January 2025
Cleveland Clinic, Cleveland, Ohio, United States.
Antibodies to β2-glycoprotein I (β2GPI) cause thrombosis in antiphospholipid syndrome, however the role of β2GPI in coagulation in vivo is not understood. To address this issue, we developed β2GPI-deficient mice (Apoh-/-) by deleting exon 2 and 3 of Apoh using CRISPR/Cas9 and compared the development of thrombosis in wild-type (WT) and Apoh-/- mice using rose bengal and FeCl3-induced carotid thrombosis, laser-induced cremaster arteriolar injury, and inferior vena cava (IVC) stasis models. We also compared tail bleeding times and activation of platelets from WT and Apoh-/- mice in the absence and presence of β2GPI.
View Article and Find Full Text PDFPre- and Postnatal Development Study of Nemolizumab, a Humanized Anti-Interleukin-31 Receptor A Monoclonal Antibody, in Cynomolgus Monkey.
Birth Defects Res
February 2025
Translational Research Division, Chugai Pharmaceutical Co. Ltd., Chuo, Japan.
Background: Nemolizumab, a humanized monoclonal antibody against interleukin-31 receptor A (IL-31RA), is used to treat atopic dermatitis and prurigo nodularis. These inflammatory skin diseases affect a wide range of age groups, including pregnant women and children; however, little is known about their biological effects on pre- and postnatal development. Therefore, we report and discuss the results of an enhanced pre- and postnatal development study in cynomolgus monkeys treated with nemolizumab, which also incorporates an assessment of juvenile toxicities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!